Dopaminergic Homeostatic Therapy (DHT^™) as a Putative Anti-Addiction Seeking Intervention and Early Identification of...

In spite of the ongoing exquisite work of a multitude of researchers worldwide including governmental institutions like the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and for example in the United States the FDA Medication Assisted Therapy (MAT) embracing Opioid Replacement Therapy (ORT) in 2022, 111,000 people prematurely died from opioid induced overdose. It is estimated that if treatment stays as usual by 2025 the death rate will increase to 165,00.Therefore, we are encouraging the scientific and clinical community to at least consider our "out of the box" thinking whereby we are proposing a new paradigm shift involving the " dopaminergic homeostatic modeling approach and Genetic screening to early identify preaddiction. In this novel approach following detoxification from for example powerful opioids, the patient is administered the validated RDSQ29 to access potential psychological profiling of Reward Deficiency Syndrome (RDS); obtain a cheek cell sample of the patient and perform genetic screening utilizing the Genetic Addiction Risk Severity (GARS); analyze mRNA to identify specific protein deficits/surfeits based on the measured reward genes involved in the Brain Reward Cascade (BRC); produce a customized pro-dopamine regulator (KB220) guided by GARS resulting polymorphisms; objectively employ the mRNA profiling assessment every week during the treatment phase to determine improvement; each treatment program could add on at their choice, for example, cognitive behavioral therapy, brain spotting, trauma therapy, electrotherapy (h-wave device to reduce pain, subluxation repair etc.) mindfulness, exercise, neuromodulation (PrTMS) amongst other modalities. The utilization of this model could prove beneficial to both substance and non-substance behavioral addictions (e. g. gaming). WC261 .